Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Adverse effects sufficient to stop treatment · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
All cause mortality (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Adverse events (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Total VTE · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
Heparin showed no clear difference in PE (symptomatic, asymptomatic, non‐fatal) (timing not specified) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis may leads to lower recurrent VTE compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Major lower GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Major non‐GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
Minor GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor lower GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review